Datatrak International, Inc. Expands Its Presence in the Asia-Pacific Region

CLEVELAND, Sept. 19, 2019 /PRNewswire/ — Datatrak International, Inc. (OTC Markets: DTRK), a worldwide Software-as-a-Service (SaaS) provider and innovation leader of cloud-based technologies for the life sciences industry, today announced that NTT Data has extended and expanded its relationship with Datatrak for an additional 5 years, through 2024.

“Under the terms of the agreement, NTT Data will expand its sales and support beyond EDC to include the larger Datatrak Enterprise Cloud for Japan and the growing Asia-Pacific market,” said Jim Bob Ward, CEO and President of Datatrak. “We are excited to build upon a 10-year partnership with NTT by offering cloud-based Business Intelligence, Clinical Trial Management (CTMS), Electronic Data Capture (EDC), lab image capture and Endpoint Adjudication (EAS), patient data capture from smartphones and tablets (ePRO),  and wearable Bluetooth devices (eCOA), all with informed consent (eConsent) through multiple languages.”

This latest extension demonstrates NTT Data’s vision as a Trusted Global Innovator and their commitment to helping their pharmaceutical, medical device, biotech and CRO clients leverage leading edge technologies like the Datatrak Enterprise Cloud to bring products to market faster and more safely. “More and more global clinical trials are being conducted in the APAC region each year,” added Shikou Sekine, Manager, Public Welfare IT Services Division, NTT Data. “We need advanced technologies to streamline the diverse challenges of conducting clinical trials and we look forward to offering the Datatrak Enterprise Cloud with ePRO and Business Intelligence to help meet our client needs.”

“Business Intelligence and patient sourced data in clinical trials (eSource) is expected to grow dramatically in the coming years. We believe our initial offering of Datatrak Direct, limited to ePRO, eCOA, and eConsent, will provide our sponsors with the ability to move closer to paperless trials while reducing operating cost by designing and managing their own studies,” said Scott DeMell, VP Sales at Datatrak.  “Datatrak Direct is a logical step to advancing the Enterprise Cloud Platform as a SaaS platform for the next generation of Virtual Trials.”

Schedule an appointment with Datatrak at DIA Japan to see the Multi-Lingual Enterprise Cloud Platform. https://bit.ly/2kjrtkm

See the news article on the website: https://bit.ly/2mnkEPx

About Datatrak International, Inc.:

Datatrak International is a worldwide technology and services company delivering unified eClinical solutions and related services for the clinical trials industry. Datatrak built its multi-component, comprehensive solution on a single, unified platform. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The Datatrak software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Pre-clinical, Phase I – Phase IV drug, device and diagnostic studies in multiple languages throughout the world.

The Datatrak Enterprise Cloud includes the following products: Clinical Trial Management System (CTMS), Trial Design, Electronic Data Capture (EDC), Medical Coding, Risk-Based Monitoring, ECG Data Capture, Image Data Capture, Endpoint Adjudication, Randomization, Clinical Supply Inventory, eConsent, ePRO, eCOA and Business Intelligence.

Visit http://www.datatrak.com

View original content:http://www.prnewswire.com/news-releases/datatrak-international-inc-expands-its-presence-in-the-asia-pacific-region-300921164.html

SOURCE Datatrak International, Inc.

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

10 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

10 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

10 hours ago